Generic Actigall ( Ursodeoxycholic acid )

Buy cheap Generic Actigall (Ursodeoxycholic acid) without dr prescription at Canadian Pharmacy

Actigall (Ursodeoxycholic Acid 300 mg): Comprehensive Patient Information for Canada

Basic Product Information

Mechanism of Action

In simple terms: Ursodeoxycholic acid is a naturally occurring bile acid that helps dissolve certain types of gallstones and improves bile flow in the liver. It works by reducing the amount of cholesterol in bile, which helps break down cholesterol-based gallstones over time. In liver diseases, it helps protect liver cells from damage caused by toxic bile acids.

For specialists: Ursodeoxycholic acid (UDCA) is a hydrophilic dihydroxy bile acid that exerts multiple hepatoprotective effects. UDCA stabilizes plasma membranes against cytolysis by tensioactive bile acids accumulated in cholestasis. It halts apoptosis by preventing the formation of mitochondrial pores, membrane recruitment of death receptors, and endoplasmic-reticulum stress. UDCA induces changes in the expression of metabolizing enzymes and transporters that reduce bile acid cytotoxicity and improve renal excretion. It also has immunomodulatory properties that limit the exacerbated immunological response occurring in autoimmune cholestatic diseases by counteracting the overexpression of MHC antigens and limiting cytokine production by immunocompetent cells. UDCA increases hepatic bile excretion, competes with endogenous bile acids for reabsorption in the ileum, and shifts the bile acid composition from hydrophobic to hydrophilic bile acids.

Pharmacokinetics

• Absorption: Approximately 60–80% of orally administered UDCA is absorbed rapidly by passive diffusion in the jejunum and upper ileum, and by active transport in the terminal ileum. Absorption is dose-dependent and decreases with higher doses. About 90% of a therapeutic dose of Actigall is absorbed in the small bowel after oral administration.
• Metabolism: After absorption, UDCA enters the portal vein and undergoes efficient extraction from portal blood by the liver (first-pass effect of 50–75%), where it is conjugated with glycine or taurine and secreted into the hepatic bile ducts. Beyond conjugation, UDCA is not altered or catabolized appreciably by the liver or intestinal mucosa. A small proportion undergoes bacterial degradation with each cycle of enterohepatic circulation, yielding 7-keto-lithocholic acid or lithocholic acid.
• Elimination: UDCA is eliminated primarily in the feces, with the renal route being a minor pathway. The biological half-life of UDCA is approximately 3.5–5.8 days. After discontinuation of treatment, UDCA concentrations in bile decrease within one week to 5–10% of steady-state concentrations.
• Onset of Action: Gallstone dissolution requires months of therapy. Complete dissolution does not occur in all patients and recurrence of stones within 5 years has been observed in up to 50% of patients who do dissolve their stones.
• Duration of Action: Steady-state concentrations of UDCA in bile are achieved after approximately 3 weeks of repeated dosing. The total UDCA concentration in bile never exceeds approximately 60% of the total bile acid concentration, even at high doses.

Uses in Daily Life and Best Practice Advice

Ursodeoxycholic acid is prescribed in Canada for the management of gallstones and certain liver conditions. Your physician will determine the appropriate use and dose based on your specific medical situation.

• Typical Uses: Dissolution of radiolucent, noncalcified gallbladder stones less than 20 mm in greatest diameter in patients who cannot undergo surgery; prevention of gallstone formation in obese patients experiencing rapid weight loss; treatment of primary biliary cholangitis (PBC); and management of hepatobiliary disorders associated with cystic fibrosis in children and adolescents aged 6–18 years.
• Administration: Take with food. Swallow tablets or capsules whole with water. Urso Forte tablets can be split into halves for appropriate dosage; do not chew.
• Monitoring: Liver transaminases should be monitored every 4 weeks for the first 3 months of treatment, then every 3 months. For gallstone dissolution, ultrasound monitoring should be performed 6–10 months after treatment initiation.
• Do Not Stop Without Medical Advice: Treatment duration for gallstone dissolution is typically 6–24 months. If stone size has not decreased within 12 months, treatment should be discontinued.

Morning vs. Evening Dosing

Ursodeoxycholic acid is typically taken 2 to 4 times daily with food. There is no specific clinical recommendation for morning versus evening dosing, but dividing the dose with meals helps with absorption and consistency. Always follow the schedule recommended by your physician.

• Divided Dosing: The daily dose is usually divided into 2 to 4 doses taken with meals.
• Consistency: Take UDCA at the same times each day to ensure steady levels and maximum effectiveness.
• Missed Dose: If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at the same time.
• Professional Guidance: Your healthcare provider may adjust the timing and frequency based on your condition and other medications.

Administration With or Without Food

Ursodeoxycholic acid should be taken with food. Taking it with meals improves absorption and helps reduce the risk of gastrointestinal upset. Urso and Urso Forte tablets should be taken with food. Do not administer with aluminum-based antacids or bile acid sequestrants, as these substances bind UDCA in the intestine and prevent its absorption.

• Take UDCA with meals or snacks.
• Swallow the tablet or capsule whole with water. Urso Forte tablets may be split in half if needed; do not chew.
• If aluminum-based antacids are needed, take them at least 2 hours after UDCA.
• If bile acid sequestrants such as cholestyramine or colestipol are needed, take them 5 hours or more after UDCA.
• Avoid taking UDCA at the same time as these interacting medications.

Interaction Warnings

Indications for Ursodeoxycholic Acid

"Off-label" means use outside the official approved indication, usually based on current medical guidelines and scientific evidence.

Dosing According to Clinical Indication

Doses should always be adjusted according to the advice of your physician and depending on your health condition. Do not exceed the recommended dose unless advised by a physician.

Side Effects and Safety Profile

Guidelines for Correct Use

• Take ursodeoxycholic acid exactly as prescribed by your physician. Do not change your dose without medical advice.
• Take the medication with food, at the same times each day.
• Swallow tablets or capsules whole with water. Urso Forte tablets may be split in half if needed; do not chew.
• Do not take UDCA at the same time as cholestyramine, colestipol, or aluminum-based antacids.
• Keep all medical appointments for monitoring of liver function, especially during the first 3 months of treatment.
• For gallstone dissolution, follow-up ultrasound examinations are important to assess treatment response.
• Inform every healthcare provider (including dentists, surgeons, and pharmacists) that you are taking ursodeoxycholic acid.
• If you are pregnant, planning to become pregnant, or breastfeeding, consult your physician. Effective contraception is recommended for women of childbearing potential during treatment.
• If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double the dose.
• Store at room temperature in a dry place. Keep out of reach of children.

Alternative Treatment Options

• Chenodiol (Chenodeoxycholic acid): Another bile acid used for gallstone dissolution. It is effective but associated with a higher incidence of diarrhea and liver enzyme elevations compared with UDCA. Seldom used now.
• Laparoscopic Cholecystectomy: Surgical removal of the gallbladder is the definitive treatment for symptomatic gallstones and is preferred for most patients who are surgical candidates.
• Extracorporeal Shock Wave Lithotripsy (ESWL): A non-invasive procedure that uses shock waves to break up gallstones. Sometimes combined with UDCA therapy.
• Obeticholic Acid: A second-line therapy for primary biliary cholangitis for patients who do not respond adequately to UDCA. Available by prescription in Canada.
• Elafibranor and Seladelpar: Newer second-line therapies for PBC, FDA-approved for patients with inadequate response to UDCA. Availability in Canada may be limited.
• Fenofibrate: Off-label second-line therapy for PBC in patients with inadequate response to UDCA.

Comparison: Ursodeoxycholic acid remains the first-line treatment for primary biliary cholangitis and is the only approved oral medication for gallstone dissolution. It is generally well tolerated with a favorable safety profile. Surgical cholecystectomy remains the definitive treatment for symptomatic gallstones. For PBC patients who do not respond adequately to UDCA, second-line therapies such as obeticholic acid, elafibranor, or seladelpar may be added. Your physician will determine the best option for your specific condition.

Legal Status, Registration, and Coverage in Canada

• Registration: Ursodiol is authorized for sale in Canada by Health Canada as a prescription drug. Generic ursodiol products are available in 250 mg and 500 mg tablets from multiple manufacturers, including Nora Pharma, Jamp Pharma, Angita Pharma, Glenmark, and others.
• Prescription Status: Prescription only in Canada.
• Coverage: Coverage varies by province and territory. In Ontario, ursodiol is listed as a Limited Use product under the Ontario Drug Benefit (ODB) formulary for the treatment of primary biliary cirrhosis (LU Code 273) and primary sclerosing cholangitis (LU Code 534). The unit price for generic ursodiol 250 mg in Ontario is approximately $0.38 per tablet. Coverage in other provinces varies.
• Pharmacovigilance: Adverse reactions should be reported to Health Canada's MedEffect Canada program.

Recent Research and Clinical Guidelines (2022–2026)

• The 2026 review on primary biliary cholangitis published in Current Hepatology Reports confirms that ursodeoxycholic acid remains the first-line treatment option for PBC. The recommended dose is 13–15 mg/kg/day. Second-line therapies such as elafibranor and seladelpar are FDA-approved for patients with inadequate response to UDCA, and evolving algorithms should consider earlier addition of second-line therapies at 6 months, especially in younger patients with increased liver stiffness.
• German clinical practice guidelines (2026) recommend ursodeoxycholic acid at a dose of 13–15 mg/kg/day as lifelong standard therapy for primary biliary cholangitis.
• Danish clinical guidelines (2026) recommend 10–12 mg/kg/day divided into 2 doses for gallstone dissolution, with treatment duration typically 6–24 months. If gallstone size does not decrease within 12 months, treatment should be discontinued.
• Nora Pharma launched a generic ursodiol product for the Canadian market in 250 mg and 500 mg tablets in November 2024. The global ursodiol market was valued at approximately $457.9 million in 2022 and is projected to reach around $933.9 million by 2029.
• Research continues to explore the role of UDCA in other liver diseases, including non-alcoholic steatohepatitis and drug-induced liver injury, but evidence for these indications remains limited.

Availability and Supply in Canada

Prices and availability may vary by province, territory, and pharmacy. Generic ursodiol is widely available in Canada and is generally more affordable than brand-name products. Check with your local pharmacy for current pricing and coverage options.

Frequently Asked Questions (FAQ)

1. What is Actigall used for?
   Actigall (ursodiol) is used to dissolve certain types of gallstones (radiolucent, noncalcified stones less than 20 mm) in patients who cannot undergo surgery, to prevent gallstone formation in obese patients experiencing rapid weight loss, and to treat primary biliary cholangitis (PBC), a chronic liver disease.
2. How long does it take for Actigall to dissolve gallstones?
   Gallstone dissolution requires months of therapy, typically 6 to 24 months. Complete dissolution does not occur in all patients, and recurrence within 5 years has been observed in up to 50% of patients who do dissolve their stones. If stone size has not decreased within 12 months, treatment should be discontinued.
3. What is the difference between Actigall 300 mg capsules and generic ursodiol tablets?
   Actigall is a brand-name 300 mg capsule formulation. Generic ursodiol is available in Canada as 250 mg and 500 mg tablets. They contain the same active ingredient (ursodeoxycholic acid) and are therapeutically equivalent when taken at equivalent doses.
4. Can I take ursodiol with other medications?
   Ursodiol can interact with cholestyramine, colestipol, aluminum-based antacids, cyclosporine, ciprofloxacin, rosuvastatin, nitrendipine, and dapsone. Always inform your physician and pharmacist about all medications and supplements you are taking before starting ursodiol.
5. What should I do if I miss a dose of ursodiol?
   If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time.
6. Can I stop taking ursodiol if I feel better?
   No. Do not stop taking ursodiol without consulting your physician. For gallstone dissolution, stopping treatment prematurely may allow stones to recur. For PBC, ursodiol is lifelong therapy that helps slow disease progression.
7. Is ursodiol safe during pregnancy?
   Ursodiol should not be used during pregnancy unless clearly necessary. Animal studies have shown reproductive toxicity during early gestation. Women of childbearing potential should use effective contraception during treatment. Consult your physician if you are pregnant, planning to become pregnant, or breastfeeding.
8. What are the signs of serious side effects I should watch for?
   Seek immediate medical attention if you experience severe right upper abdominal pain, signs of liver decompensation (confusion, yellowing of skin or eyes, abdominal swelling), or severe allergic reactions (rash, hives, difficulty breathing, swelling of the face or throat).
9. Is ursodiol covered by Canadian health insurance?
   Coverage varies by province and territory. In Ontario, ursodiol is covered under the ODB formulary as a Limited Use product for primary biliary cirrhosis and primary sclerosing cholangitis. Check with your provincial or territorial drug plan and private insurance provider for coverage details.

How to buy Generic Actigall without rx in Canada.